Regarding its function for the pathogenesis of CIDP, we assume that the decrease of CD32b on naïve B cells is not clinically relevant for the following reasons: 1) CD32b is known to decline subsequent to IVIg treatment on naïve B cells in CIDP within the first week (Dyer et al. 2016). This evidence concerns the gene FCGR2B and chronic inflammatory demyelinating polyradiculoneuropathy.